Topic: checkpoint inhibitors
Alphamab Oncology has raised $100 million to advance a broad pipeline of treatments for infertility, ophthalmology and infection, as well as oncology.
Combining a RIP1 inhibitor with Merck's hit checkpoint inhibitor Keytruda holds promise in treating pancreatic cancer, GSK says.
SITC kicked off with a stack of new data on immuno-oncology drugs, including a first look at Merck’s early-stage drugs targeting LAG-3 and TIGIT.
The Big Pharma is investing $12 million in Compugen as part of a deal that gives it the right to first negotiations for the COM701 license.
Allison and Honjo set the stage for the current immuno-oncology boom in the 1990s by discovering the cancer-killing potential of CTLA-4 and PD-1.
The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells in preclinical tests.
The series B equips execs that cut their teeth at top multinational drugmakers to advance autoimmune and cancer candidates through the clinic.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
The deal gives AbbVie the global rights to an anti-GARP antibody designed to block the immunosuppressive activity of regulatory T cells.
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China.